Antibodies directed against the capsular polysaccharide (polyribosyl ribitol phosphate [PRP]) or the outer membrane proteins (OMP) of Haemophilus influenzae type b (Hib) promote bactericidal activity, complement 3 (C3) binding, and ingestion by phagocytic cells. To assess the relative contribution of anti-OMP to host defense against Hib, we compared the opsonic activities of anti-PRP and anti-OMP as reflected by the amounts of C3 bound to the bacterial surface. Immunoglobulin G (IgG) fractions containing either anti-PRP or anti-OMP were incubated with Hib in the presence of a C5-deficient complement source. C3, total IgG, and IgG subclasses bound to the bacteria were quantified by enzyme-linked immunosorbent assay. The maximum amount of C3 which could be bound to Hib was greater in the presence of anti-PRP than in the presence of anti-OMP. Also, except at low IgG concentrations, the rate of increase in bound C3 as a function of increasing IgG concentration was greater for anti-PRP than for anti-OMP. Hib-bound anti-OMP consisted primarily of IgGl and IgG3, whereas bound anti-PRP was primarily IgGl and IgG2. Thus, the potential for C3 binding to Hib is greater in the presence of anti-PRP than in the presence of anti-OMP, probably because of the larger number of binding sites available to the former. Nonetheless, OMP appear to provide important targets for opsonic antibody and would be logical components of a PRP-conjugate vaccine or may be efficacious as vaccines against nontypeable H. influenzae.
Haemophilus influenzae type b (Hib) has been the major cause of meningitis in infants and children less than 5 years of age (29) . Recently developed vaccines consisting of capsular polysaccharide (polyribosyl ribitol phosphate [PRP]) conjugated to a protein are immunogenic in infants as young as 2 months and should significantly reduce the incidence of Hib disease in the United States (8, 18, 21) .
The mechanism by which anti-PRP antibodies provide protection is uncertain. Bactericidal activity may be important, but it is not sufficient by itself, as many infants possess serum bactericidal activity at the time of acute presentation of Hib meningitis (33) . In animal models, bacteremia appears to be cleared through opsonophagocytosis, a process in which complement plays a crucial role (6, 26, 31) .
Non-PRP-directed antibodies also participate in host defense against Hib (1, 7, 14, 19, 34) . We recently showed that serum antibodies to the outer membrane proteins (OMP) of Hib in healthy adults cause the majority of complement 3 (C3) binding to the bacterial surface (11) . In the present study, we compared C3 binding in the presence of anti-PRP and anti-OMP, first examining the relative dose-response binding of the antibodies and then quantifying C3 binding to Hib at increasing concentrations of each antibody. The potential contribution of antilipopolysaccharides was excluded, as these antibodies do not appear to offer protection or to be major activators of complement (7, 12, 27, 34) .
(This paper was presented in part to the American Federation for Clinical Research, 5 MATERIALS AND METHODS Sera. Pooled serum from adults immunized with PRP conjugated to diphtheria toxoid (immune serum) was the gift of Patrick McVerry (Connaught Laboratories, Swiftwater, Pa.); it contains 160 jig of anti-PRP per ml by radioimmunoassay (RIA). Serum from a healthy adult (unimmunized) was used as the source for anti-OMP. C5-deficient (C5D) serum (Quidel, San Diego, Calif.) was used as a source of complement to prevent bacterial lysis. In preliminary experiments, we noted that the addition of Mg-EGTA [ethylene glycolbis(,-aminoethyl ether)-N,N,N',N'-tetraacetic acid], which selectively blocks classic pathway complement activation, did not reduce C3 deposition (data not shown). Thus, our C5D complement source supported both classic and alternative pathway complement activation. Naturally occurring antibodies were removed from C5D serum by absorption with glutaraldehyde-fixed Hib at 4°C (13) . Anti-OMP and anti-PRP were undetectable in the absorbed C5D serum by enzyme-linked immunosorbent assay (ELISA) and RIA.
Bacteria. For all experiments, we used the Eagan strain of Hib in log-phase growth. The bacteria were prepared as previously described and suspended in phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA) (pH 7.4) at 1 x 109 to 2 x 109 CFU/ml (11).
IgG fractions. The immunoglobulin G (IgG) fraction of healthy serum was prepared by treatment with caprylic acid at pH 4.8 (35) . The supernatant was filtered, dialyzed sequentially against PBS and sodium phosphate buffer (0.005 M, pH 6.2), and applied to a DEAE-Sephacel column (2.5 by 17 cm). Fractions in the optical density (OD) peak of 280 nm were pooled, vacuum dialyzed against PBS, and stored at -70°C. The IgG fraction from postimmunization serum was prepared by initial gel filtration over an ACA-34 column (1.5 by 75 cm) equilibrated with 0.1 M Tris buffer (pH 8.0).
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Eluent fractions were screened by ELISA for immunoglobulin isotype. Those containing IgG were pooled and applied to the DEAE-Sephacel column as described above (30) .
Preparation of anti-PRP and anti-OMP fractions. Because of the potential problems of selective desorption and functional disruption with the preparation of affinity-purified antibody, we chose to absorb anti-PRP antibody from the anti-OMP fraction and vice versa. The anti-PRP IgG fraction was derived from the IgG fraction of postimmunization serum. Non-PRP-directed antibodies were removed by affinity chromatography. We prepared an outer membrane complex (OMC) containing membrane proteins and lipopolysaccharide (LPS), as previously described (9, 24) . OMC protein (13 mg) was covalently bound to 2.5 ml of cyanogen bromide-activated Sepharose 4B (23) . One milliliter of the IgG fraction from immunized donors (0.67 mg) was applied to the affinity column and incubated for 1 h at 4°C. The unbound IgG was collected and assayed for anti-OMP and anti-PRP by ELISA and RIA, respectively (see below). Total IgG was determined by the A280, with an extinction coefficient of 1.4. The final IgG fraction was designated anti-PRP IgG.
Anti-OMP IgG was prepared from the IgG fraction of healthy serum. Anti-PRP was removed by affinity chromatography. We prepared an affinity column by reacting 20 mg of PRP with benzoquinone and subsequently covalently binding the PRP to 10 ml of washed AH-Sepharose (16) . Twenty-six milligrams of the IgG fraction from healthy serum was applied to the column and incubated for 2 h at 4°C. The IgG was eluted and assayed for anti-OMP, anti-PRP, and total IgG. The amount of anti-OMP IgG added in the opsonization assays is reported as total IgG added because no standard method for quantifying specific anti-OMP is available.
We assessed the anti-OMP and the absorption procedures by immunoblot. OMC was diluted to 0.8 mg of protein per ml in reducing buffer, heated to 100°C, and separated on a 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel by the method of Laemmli (17) . Proteins were transferred to nitrocellulose paper by the method of Towbin et al. (36) . Nonspecific binding sites were blocked by overnight incubation at 4°C in 0.01 M Tris buffer (pH 7.4) with 0.15 M NaCl and evaporated milk (2:1). The nitrocellulose paper was placed in a Deca-Probe apparatus (Hoeffer Scientific, San Francisco, Calif.). We added the IgG fractions (0.1 mg/ml), diluted in PBS containing 3% BSA and 0.05% Tween 20, to individual lanes and incubated the immunoblot for 3 h at room temperature. The immunoblot was washed four times with the diluent described above, and a goat anti-human IgG biotin conjugate (Sigma Chemical Co., St. Louis, Mo.) was applied to all lanes at a dilution of 1:2,000. After 1 h, the washing was repeated and the immunoblot was incubated in ExtrAvidin-alkaline phosphatase (Sigma) diluted 1:3,000. After this final 1-h incubation, the immunoblot was washed again and incubated for 30 min in fast red (3 mg/ml) and naphthol-AS MX phosphate (3-hydroxy-2-naphthoic acid 2,4-dimethylanilide phosphate) (0.2 mg/ml) in 0.1 M Tris buffer (pH 8.2).
ELISA for anti-OMP. The LPS was removed from OMC by repeated gel filtration over a Bio-Gel P-100 column (1.5 by 85 cm) equilibrated with sodium deoxycholate buffer as previously described (9) . The final product contained 2.3 mg of protein per ml by the Lowry protein assay and no detectable LPS by silver staining following SDS-polyacrylamide gel electrophoresis (17, 20) . This purified OMP preparation was used to coat 96-well microtiter plates for the determination of anti-OMP IgG as previously described (11) . Since no recognized method of quantitation of anti-OMP is available, results were recorded as (i) the dilution of sample that yielded an OD of 0.1 and (ii) the percentage of anti-OMP depleted by affinity chromatography, calculated after normalizing for the total IgG content.
RIA for anti-PRP. We measured the anti-PRP concentrations of our C5D serum and IgG fractions by RIA (10, 28) . Tritiated PRP was provided by Porter Anderson (University of Rochester, Rochester, N.Y.), and the assay was standardized with serum from the Food and Drug Administration (70 ,ug of anti-PRP per ml).
C3 and total IgG binding assays. We measured C3 and total IgG bound to Hib by our previously described method (11) . Hib (108 CFU/ml) was incubated with 10% C5D serum plus anti-PRP or anti-OMP IgG in PBS-BSA for 30 min at 37°C with shaking. The bacteria were placed in an ice bath, centrifuged, and brought to the original volume with Hank's balanced salt solution containing 0.1% gelatin. Aliquots (50 ,ul each) of opsonized Hib were added to duplicate tubes containing 100 ,ul of diluted goat anti-human C3 or goat anti-human IgG-peroxidase conjugates. After 1 h of incubation at 4°C, Hib was washed three times with PBS-BSA. We added 200 ,u1 of o-phenylenediamine substrate (0.4 mg/ml) to the washed pellets, and the reaction was stopped after 30 min. The results were recorded as the OD at 490 nm after subtraction of background OD: those generated by heatinactivated C5D-opsonized Hib for C3 and buffer-opsonized Hib for IgG.
Subclasses of Hib-bound IgG. By modifying the assay described above, we were able to quantify the subclasses of IgG bound to Hib. After opsonization, Hib was washed three times with PBS-BSA. Washed, opsonized Hib (50 ,ul) was added to duplicate tubes containing 100 p.I of monoclonal antibodies to each IgG subclass (IgGl, clone HP-6001; IgG2, clone HP-6014; IgG3, clone HP-6050; IgG4, clone HP-6025; Sigma). All monoclonal antibodies were obtained as ascites fluid and diluted 1:1,000 in PBS-BSA. After 1 h of incubation at 4°C, Hib was washed as described above, and 100 ,ul of goat anti-mouse IgG (absorbed with human IgG)-alkaline phosphatase conjugate diluted 1:1,000 in PBS-BSA (Sigma) was added. After another 1 h of incubation and washing, we added 200 ,ul of p-nitrophenyl phosphate reagent (1 mg of p-nitrophenyl phosphate per ml in diethanolamine buffer; pH 9.8). The reaction was stopped after 30 min with 100 ,u1 of 1 N NaOH, and the OD at 405 nm were recorded. Backgrounds were derived from tubes containing identical reagents but no bacteria.
RESULTS
Absorption of IgG fractions. The absorption of PRP immune serum with OMC by affinity chromatography depleted most of the anti-OMP detectable by immunoblot (Fig. 1) . Small amounts of antibody directed against a 39-kDa band (P2) and a 16-kDa band (P6) remained. Absorption of PRPdirected antibodies from our anti-OMP IgG did not significantly alter the spectrum of anti-OMP present. Antibodies against proteins of 105, 98, 56, 49 (P1), 39 (P2), 35, 32, and 16 (P6) kDa were present.
Opsonization with anti-PRP. The amount of IgG bound to the surface of Hib cells increased over the entire range of anti-PRP concentrations, from 0.06 to 2.0 ,ug/ml (Fig. 2) anti-PRP per ml; the higher concentration of 2.0 ,ug of anti-PRP per ml did not result in more bound C3.
Opsonization with anti-OMP. The kinetics of anti-OMP binding were quite different from those of anti-PRP. The maximum amount of bound IgG was detected at the lowest concentration of total IgG tested (0.25 mg/ml) (Fig. 3) . Addition of higher concentrations did not increase IgG binding; however, the amount of bound C3 rose over the range of IgG concentrations tested. Although a saturating amount of bound C3 was not reached, we major subclasses bound, as would be expected for proteindirected antibodies (Fig. 5) . Smaller amounts of IgG2 and negligible amounts of IgG4 were detected on the bacterial surface. The fourfold increase in added IgG concentration resulted in 77 and 37% increases in IgGl binding and IgG3 binding, respectively, but had no effect on IgG2 binding. These findings contrast with a 94% increase in C3 binding (Table 1 ) and are at odds with the lack of increase in total IgG binding as detected by the above-described method with polyclonal anti-human IgG.
We performed the same assay for anti-PRP IgG with concentrations of 0.25 and 1.0 ,ug of anti-PRP per ml. The results showed the expected predominance of IgGl and IgG2 subclass binding to the bacterial surface ( Fig. 6 ) with minimal IgG3 and negligible IgG4 binding. Binding of IgGl and IgG2 subclasses increased with higher concentrations of added anti-PRP, paralleling the results for total bound IgG and bound C3. DISCUSSION We previously demonstrated that in serum from unvaccinated adults, antibodies against OMP, not the capsular 2 ) and the averages of duplicates from a single experiment for subclass binding (from Fig. 5) .
b Refers to increase in OD with IgG concentration increasing from 0.25 to 1.0 mg/ml. polysaccharide, mediate the majority of C3 binding to Hib cells (11) . However, immunization with PRP or PRP-conjugate vaccines elicits antibody that is opsonic and bactericidal (5, 25) . In the present study, we compared the binding properties of (and complement activation by) anti-OMP and anti-PRP, using IgG fractions absorbed with PRP or OMC.
The most notable characteristic of binding by anti-OMP IgG was that the Hib surface apparently became saturated at low total IgG concentrations. The continued increase of C3 binding at higher concentrations of added IgG while IgG binding remained unchanged (or even slightly decreased) is puzzling. It could be that anti-OMP, which contribute least to the total IgG bound, contribute most to C3 deposition. Highly exposed OMP could be immunodominant and bind IgG readily. C3 bound as a result of such IgG, however, by virtue of high surface exposure, might also be rapidly inactivated by serum factors H and I. The result would be decreased half-life of C3 convertase and limited amplification of C3 binding (4) . IgG bound to less-exposed OMP, whose binding sites are saturated only at higher concentrations of IgG, may result in bound C3 less likely to be inactivated and therefore may contribute more to total bound C3. Studies examining IgG and C3 binding to individual OMP are required to answer these questions.
Although limited by a technique that is based on arbitrary OD units (and hence is only semiquantitative), our results permit two generalizations concerning the relative C3 deposition capabilities of anti-OMP and anti-PRP. First, the maximal amount of C3 which can be bound to Hib is greater in the presence of anti-PRP than in the presence of anti-OMP. C3 deposition in the presence of anti-PRP yielded an OD of 0.406 compared with an OD of 0.225 for anti-OMP. Moreover, 2.13 OD units of IgG bound to Hib (1 ,ug of anti-PRP per ml) were required to achieve the maximum C3 deposition for anti-PRP (Fig. 2) , but only 0.431 OD units were required for anti-OMP (compare Fig. 3) . Second, at low IgG concentrations, the increase in bound C3 as a function of IgG concentration is similar for anti-OMP and anti-PRP (Fig.  4) . For example, doubling the anti-PRP concentration from the anti-OMP concentration) of our anti-OMP IgG fraction from 0.25 to 0.5 mg/ml increased C3 binding by 0.050 OD units. At higher antibody concentrations, the increase in bound C3 was proportional to the concentration of added anti-PRP, while the rate of increase of C3 binding decreased with anti-OMP, probably as a result of limited antibody targets.
The finding of similar C3-binding efficiencies for anti-PRP and anti-OMP at low IgG concentrations was unexpected. Classic pathway activation and resultant C3 binding requires a critical density of surface-bound IgG, because Clq binds when two or more IgG molecules are a critical distance apart (3) . At low total IgG binding, the effect of additional IgG on the surface would be less likely to initiate C3 binding if the surface is large, since the chance that two or more IgG molecules are within the critical distance for Clq binding is lower. This simplistic model may be inadequate for Hib, because although the capsule is a homogenous antigen, the outer membrane is not. Clustering of proteins would also negate the model, although findings by some investigators suggest that the OMP are not clustered on Hib (15) .
Another reason we did not expect to find similar C3-binding efficiencies at low IgG concentrations relates to the IgG subclasses bound. Bound anti-OMP appear to be IgGl and IgG3, with less IgG2. By contrast, anti-PRP is predominantly IgGl and IgG2, reflecting immune responses to PRP vaccines (22, 32) . Recent evidence, however, suggests that IgGl, followed by IgG3, has the greatest capacity to cause C3 binding (2) . We therefore anticipated that, for a given amount of bound IgG, anti-OMP would have caused more C3 deposition than anti-PRP and that the increase in C3 binding for a given increase in bound IgG would have been greater for anti-OMP. This hypothesis was not substantiated by our results. Other factors such as IgG exposure or type of C3 fragment bound may be more important.
The results we have obtained must be interpreted within the limitations of the techniques used. Some anti-PRP did remain in our anti-OMP IgG fraction. At the concentrations used, the anti-PRP concentration in the anti-OMP IgG ranged from 0.017 to 0.125 jxg/ml. Thus, the maximal C3-binding capacity of anti-OMP may be lower than calculated, but the contribution of anti-PRP at low anti-OMP concentrations would be negligible. ELISA showed that no anti-OMP persisted in the anti-PRP IgG, and only small amounts were detected by immunoblot; hence, at the dilutions of anti-PRP used, no significant contribution to C3 binding by anti-OMP could be expected. Finally, the anti-OMP we used were heterogeneous, so the C3-binding activity of anti-OMP represents an average of that of the heterogeneous antibodies.
Additional questions were raised by these results. For example, which OMP are the targets of opsonic (as defined by C3 binding) antibody? Studies to answer this and other questions on the biochemical events of C3 binding to the Hib surface are needed. The clinical significance of our research is that a specific OMP target for opsonic antibody may be a logical component of a PRP-conjugate vaccine. Such an antigen could also be useful as a vaccine against infections caused by nontypeable H. influenzae.
